316 related articles for article (PubMed ID: 8097038)
1. Molecular targets in oncology: implications of the multidrug resistance gene.
Lum BL; Gosland MP; Kaubisch S; Sikic BI
Pharmacotherapy; 1993; 13(2):88-109. PubMed ID: 8097038
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and chemosensitization of transgenic mice which express the human multidrug resistance gene in bone marrow: efficacy, potency, and toxicity.
Mickisch GH; Licht T; Merlino GT; Gottesman MM; Pastan I
Cancer Res; 1991 Oct; 51(19):5417-24. PubMed ID: 1680550
[TBL] [Abstract][Full Text] [Related]
3. Molecular mechanism of multidrug resistance in tumor cells.
Roninson IB
Clin Physiol Biochem; 1987; 5(3-4):140-51. PubMed ID: 2887329
[TBL] [Abstract][Full Text] [Related]
4. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
5. Multidrug resistance mediated by P-glycoprotein in haematological malignancies.
Pasman PC; Schouten HC
Neth J Med; 1993 Jun; 42(5-6):218-31. PubMed ID: 8104318
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
Willman CL
Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
[TBL] [Abstract][Full Text] [Related]
7. MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.
Lum BL; Gosland MP
Hematol Oncol Clin North Am; 1995 Apr; 9(2):319-36. PubMed ID: 7642466
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver.
Arora A; Seth K; Shukla Y
Carcinogenesis; 2004 Jun; 25(6):941-9. PubMed ID: 14729595
[TBL] [Abstract][Full Text] [Related]
10. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
11. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
12. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
Arora A; Seth K; Kalra N; Shukla Y
Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
[TBL] [Abstract][Full Text] [Related]
13. Drug resistance in multiple myeloma.
Sonneveld P
Pathol Biol (Paris); 1999 Feb; 47(2):182-7. PubMed ID: 10192886
[TBL] [Abstract][Full Text] [Related]
14. Multidrug resistance: a transport system of antitumor agents and xenobiotics.
Tsuruo T
Princess Takamatsu Symp; 1990; 21():241-51. PubMed ID: 1983721
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
16. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells. The clinical significance of MDR protein overexpression.
Bodey B; Taylor CR; Siegel SE; Kaiser HE
Anticancer Res; 1995; 15(6B):2461-8. PubMed ID: 8669809
[TBL] [Abstract][Full Text] [Related]
18. Modulators of multidrug resistance. Preclinical studies.
Ford JM
Hematol Oncol Clin North Am; 1995 Apr; 9(2):337-61. PubMed ID: 7642467
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance: prospects for clinical management.
Mansouri A; Henle KJ; Nagle WA
SAAS Bull Biochem Biotechnol; 1992 Jan; 5():48-52. PubMed ID: 1375033
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein-mediated multidrug resistance and cytotoxic effector cells.
Savas B; Cole SP; Akoglu TF; Pross HF
Nat Immun; 1992; 11(4):177-92. PubMed ID: 1358293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
